Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting.
Cell therapy has the potential to impact the quality of life of suffering patients. Systemic infusion is a convenient method of cell delivery; however, the efficiency of engraftment presents a major challenge. It has been shown that modification of the cell surface with adhesion ligands is a viable approach to improve cell homing, yet current methods including genetic modification suffer potential safety concerns, are practically complex and are unable to accommodate a wide variety of homing ligands or are not amendable to multiple cell types. We report herein a facile and generic approach to transiently engineer the cell surface using lipid vesicles to present biomolecular ligands that promote cell rolling, one of the first steps in the homing process. Specifically, we demonstrated that lipid vesicles rapidly fuse with the cell membrane to introduce biotin moieties on the cell surface that can subsequently conjugate streptavidin and potentially any biotinylated homing ligand. Given that cell rolling is a pre-requisite to firm adhesion for systemic cell homing, we examined the potential of immobilizing sialyl Lewis X (SLeX) on mesenchymal stem cells (MSCs) to induce cell rolling on a P-selectin surface, under dynamic flow conditions. MSCs modified with SLeX exhibit significantly improved rolling interactions with a velocity of 8 microm/s as compared to 61 microm/s for unmodified MSCs at a shear stress of 0.5 dyn/cm(2). The cell surface modification does not impact the phenotype of the MSCs including their viability and multi-lineage differentiation potential. These results show that the transitory modification of cell surfaces with lipid vesicles can be used to efficiently immobilize adhesion ligands and potentially target systemically administered cells to the site of inflammation.
Sarkar
Debanjan
D
Harvard-MIT Division of Health Sciences and Technology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, 65 Landsdowne Street, Cambridge, MA 02139, USA.
Vemula
Praveen K
PK
Zhao
Weian
W
Gupta
Ashish
A
Karnik
Rohit
R
Karp
Jeffrey M
JM
D017667:Adipocytes / Q000166:cytology*; D018929:Cell Culture Techniques / Q000379:methods*; D002454:Cell Differentiation; D017690:Cell Transplantation / Q000379:methods*; D002478:Cells, Cultured; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D010006:Osteoblasts / Q000166:cytology*
D008081:Liposomes
FASEB J. 2007 Dec;21(14):3917-27
17622670
Agents Actions Suppl. 1993;41:153-64
8317339
Eur J Immunol. 1998 Feb;28(2):433-43
9521050
Arthritis Rheum. 2002 Dec;46(12):3349-60
12483742
Stem Cells. 2007 Nov;25(11):2896-902
17901396
Biophys J. 2003 Apr;84(4):2671-90
12668476
Annu Rev Neurosci. 1989;12:227-53
2648950
Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S18-22
16501624
Stem Cells. 2004;22(7):1128-33
15579633
Nat Rev Immunol. 2007 Sep;7(9):678-89
17717539
Biophys J. 2002 Apr;82(4):1835-47
11916843
Biomaterials. 2009 Aug;30(22):3702-10
19375791
J Pathol. 2009 Jan;217(2):318-24
19023885
Nat Rev Immunol. 2008 Sep;8(9):726-36
19172693
Nature. 1997 Jun 5;387(6633):569-72
9177342
J Bone Joint Surg Am. 2004 Jul;86(7):1541-58
15252108
Traffic. 2008 Sep;9(9):1414-24
18445120
Mol Ther. 2008 Mar;16(3):571-9
18253156
Expert Opin Biol Ther. 2007 Jul;7(7):965-73
17665987
Biophys J. 2003 Oct;85(4):2720-31
14507735
Trends Immunol. 2007 May;28(5):219-26
17400510
Bioconjug Chem. 2008 Nov 19;19(11):2105-9
18973352
Stem Cells. 2007 Mar;25(3):712-7
17138964
Microcirculation. 2000 Dec;7(6 Pt 1):385-94
11142335
Circulation. 2003 Aug 19;108(7):863-8
12900340
Nat Med. 2008 Feb;14(2):181-7
18193058
Cell Stem Cell. 2009 Mar 6;4(3):206-16
19265660
Leukemia. 2003 Jan;17(1):160-70
12529674
Bioconjug Chem. 2008 Aug;19(8):1640-51
18616313